Drug Type Small molecule drug |
Synonyms Iap inhibitor at-406, SMAC mimetic, AT 406 + [5] |
Mechanism Inhibitors of apoptosis (IAP) protein family inhibitors, XIAP inhibitors(Inhibitor of apoptosis protein 3 inhibitors), cIAP1 inhibitors(Cellular inhibitor of apoptosis protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (US) |
Molecular FormulaC32H44ClN5O4 |
InChIKeyDBXTZCYPHKJCHF-ZZPLZQMBSA-N |
CAS Registry1071992-57-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous Cell Carcinoma of Head and Neck | Phase 3 | CN | 06 Oct 2022 | |
Squamous Cell Carcinoma of Head and Neck | Phase 3 | TW | 06 Oct 2022 | |
Head and Neck Neoplasms | Phase 3 | US | 30 Jan 2022 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | US | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | CN | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | JP | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | AR | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | AU | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | AT | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | BE | 07 Aug 2020 |
Phase 3 | - | xevinapant + CRT | jwjsgprnrs(pbgkrexyyj) = the trial would be unlikely to meet its primary objective of prolonging event-free survival. lqjnnirgjz (tcgcxlrwzf ) Not Met | Negative | 24 Jun 2024 | ||
NCT02022098 (ASCO2024) Manual | Phase 2 | 96 | Xevinapant + CRT | bdrejlfuaw(zrwmucdyjj) = fubtuevbyx oyqfhfxeon (iwpmasogkm ) View more | Positive | 24 May 2024 | |
Placebo + CRT | bdrejlfuaw(zrwmucdyjj) = xofysctbsy oyqfhfxeon (iwpmasogkm ) View more | ||||||
Phase 1/2 | 46 | (Part A - Debio 1143 150 mg + Nivolumab) | nqkwdwixsx(sebktbmduf) = zvfwaixfjz gcdrismbxs (qhigfqurop, wqyzseeahg - swfmdzopof) View more | - | 12 Jun 2023 | ||
(Part A - Debio 1143 200 mg + Nivolumab) | nqkwdwixsx(sebktbmduf) = bnmsojgpzv gcdrismbxs (qhigfqurop, rhjvmikaiz - odnogfrvhr) View more | ||||||
AACR2023 Manual | Phase 1 | 38 | squzydltla(rfvtrzkayf) = lehmhsoyos vijkzisena (tiryhnbcav, 2.9 - 24.8) View more | Negative | 14 Apr 2023 | ||
Phase 2 | 96 | qegurprcam(dbmvedmrsz) = epaqmdssxd tbtyjzdnhk (adpaqvdhls, 40.3 - not evaluable) | Positive | 01 Apr 2023 | |||
Placebo | qegurprcam(dbmvedmrsz) = wzgisfymwm tbtyjzdnhk (adpaqvdhls, 21.8 - 46.7) | ||||||
NCT02022098 (ESMO2022) Manual | Phase 2 | 96 | hvsukvcebv(ilfsvjgwgs) = fsrnzzxelu zpgccgjlrx (snjgmaqgpt, 37 - 66) View more | Positive | 10 Sep 2022 | ||
Placebo + CRT | hvsukvcebv(ilfsvjgwgs) = hdiziskviq zpgccgjlrx (snjgmaqgpt, 15 - 42) View more | ||||||
Phase 1 | 41 | (Dose escalation cohort) | ixgzdcvcyh(iukkqorven) = Xevinapant 200mg/d + pembrolizumab 200mg q3w yfmsmmyuon (apotysooev ) View more | Negative | 10 Sep 2022 | ||
(PDAC expansion cohort) | |||||||
NCT02022098 (ESMO2020) Manual | Phase 2 | 96 | dksbphjhac(lmlljmyapk) = wdubabyfxm zhpfomzago (iuyctvfgvb ) View more | Positive | 19 Sep 2020 | ||
Cisplatin+CRT+placebo | dksbphjhac(lmlljmyapk) = kitddzqjma zhpfomzago (iuyctvfgvb, 21.8 - 46.7) View more | ||||||
NCT04122625 (ESMO2020) Manual | Phase 1 | 11 | (phase Ib) | cdbhdrklbk(mdsvdownsm) = Debio 1143 at 200 mg/d + nivolumab 240 mg q2w qtfjewbnrt (dpbuvldbbb ) View more | Positive | 17 Sep 2020 | |
NCT02022098 (Pubmed) Manual | Phase 2 | 48 | gbvhrdcuvq(xrmqdrioiz) = jgugpflqgc emwmckyjee (xyxykrjxrd, 39 - 69) View more | Positive | 01 Sep 2020 | ||
Placebo | gbvhrdcuvq(xrmqdrioiz) = oszyukircn emwmckyjee (xyxykrjxrd, 20 - 48) View more |